Michael is a Managing Director within KPMG’s Deal Advisory and Strategy guiding private equity and strategic buyers through all stages of the M&A lifecycle, assessing acquisition targets, managing cross-functional diligence, separation and integration efforts, and leading multi-disciplinary initiatives to identify and deliver value within their portfolio.
Michael has over 18 years of experience as an advisor across private equity, drug development, healthcare provider, pharmacy, medical device, DTP retail, lab/diagnostics, and payer/PBM; with deep expertise in emerging technologies, business models, and advanced analytics and clinical data hubs. At the intersection of technology and operations, he helps investors understand and improve key systems and processes by identifying gaps and informing plans to de-risk, differentiate, enhance, and scale. More specifically, due to Michael’s deal work, he has a breadth of experience, both operationally and functionally with the majority of leading healthcare and life sciences solutions, including the vast majority of clinical trial technologies. This exposure required Michael to assess current solutions and compare capabilities and potential fit of competitor solutions and provide recommendations.
Prior to KPMG, Michael was a Senior Principal at West Monroe where he led its healthcare and life sciences M&A practice which oversaw more than 150 healthcare and life sciences transactions and 50 post-close engagements each year. Previously, he was a senior healthcare attorney representing large health systems and pharmaceutical companies in various regulatory and transactional matters.